Viva Biotech Holdings (VBIZF)
OTCMKTS
· Delayed Price · Currency is USD
0.2270
0.00 (0.00%)
At close: Apr 14, 2025
Viva Biotech Holdings Revenue
In the year 2024, Viva Biotech Holdings had annual revenue of 1.99B CNY, down -7.84%. Viva Biotech Holdings had revenue of 1.00B in the half year ending December 31, 2024, a decrease of -20.93%.
Revenue
1.99B CNY
Revenue Growth
-7.84%
P/S Ratio
1.51
Revenue / Employee
962.99K CNY
Employees
2,063
Market Cap
410.89M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| SS Innovations International | 20.65M |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Viva Biotech Holdings News
- 4 weeks ago - Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection - PRNewsWire
- 4 weeks ago - Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D - PRNewsWire
- 4 months ago - Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion - PRNewsWire
- 8 months ago - Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms - PRNewsWire
- 1 year ago - Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future - PRNewsWire
- 1 year ago - Viva Biotech Secures Approximately US$ 210 Million Funding - PRNewsWire
- 1 year ago - Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability - PRNewsWire
- 1 year ago - Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs - PRNewsWire